Financhill
Buy
57

SRPT Quote, Financials, Valuation and Earnings

Last price:
$97.17
Seasonality move :
18.62%
Day range:
$97.06 - $100.00
52-week range:
$97.06 - $173.25
Dividend yield:
0%
P/E ratio:
42.63x
P/S ratio:
5.70x
P/B ratio:
6.17x
Volume:
874.2K
Avg. volume:
955.2K
1-year change:
-21.47%
Market cap:
$9.4B
Revenue:
$1.9B
EPS (TTM):
$2.28

Analysts' Opinion

  • Consensus Rating
    Sarepta Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 1 Hold rating, and 1 Sell rating.
  • Price Target Upside
    According to analysts' consensus price target of $178.55, Sarepta Therapeutics has an estimated upside of 83.71% from its current price of $97.19.
  • Price Target Downside
    According to analysts, the lowest downside price target is $75.00 representing 22.83% downside risk from its current price of $97.19.

Fair Value

  • According to the consensus of 14 analysts, Sarepta Therapeutics has 83.71% upside to fair value with a price target of $178.55 per share.

SRPT vs. S&P 500

  • Over the past 5 trading days, Sarepta Therapeutics has underperformed the S&P 500 by -3.47% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Sarepta Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Sarepta Therapeutics has grown year-over-year revenues for 29 quarters straight. In the most recent quarter Sarepta Therapeutics reported revenues of $658.4M.

Earnings Growth

  • Sarepta Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Sarepta Therapeutics reported earnings per share of $1.50.
Enterprise value:
9.2B
EV / Invested capital:
--
Price / LTM sales:
5.70x
EV / EBIT:
33.00x
EV / Revenue:
4.84x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-26.12x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
29.07x
Gross Profit (TTM):
$1.6B
Return On Assets:
6.73%
Net Income Margin (TTM):
12.37%
Return On Equity:
20.83%
Return On Invested Capital:
10.04%
Operating Margin:
24.56%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $933M $1.2B $1.9B $396.8M $658.4M
Gross Profit $793M $1.1B $1.6B $352.6M $526.1M
Operating Income -$536.2M -$267.8M $218.1M $24.6M $161.7M
EBITDA -$594.9M -$453.7M $316.9M $57M $186.7M
Diluted EPS -$8.03 -$5.83 $2.28 $0.76 $1.50
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $2.5B $2.6B $2.6B $2.6B $3.1B
Total Assets $3B $3.1B $3.1B $3.3B $4B
Current Liabilities $416M $452.7M $619.6M $653.7M $731.7M
Total Liabilities $2.2B $2.2B $2.7B $2.4B $2.4B
Total Equity $761.8M $928M $385M $859.3M $1.5B
Total Debt $992.5M $1.1B $1.5B $1.2B $1.1B
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations -$325.3M -$501M -$205.8M -$54.7M $92M
Cash From Investing -$1B -$165.8M $755.6M -$64.4M $764.1M
Cash From Financing $232.5M $125M $124.8M $1.9M $49M
Free Cash Flow -$357.6M -$588.3M -$352.7M -$73.7M $54M
SRPT
Sector
Market Cap
$9.4B
$38.4M
Price % of 52-Week High
56.1%
45.53%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.78%
1-Year Price Total Return
-21.47%
-39.05%
Beta (5-Year)
0.794
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $101.92
200-day SMA
Sell
Level $126.20
Bollinger Bands (100)
Sell
Level 108.68 - 127.08
Chaikin Money Flow
Sell
Level -59.4M
20-day SMA
Sell
Level $104.73
Relative Strength Index (RSI14)
Sell
Level 33.99
ADX Line
Sell
Level 29.26
Williams %R
Buy
Level -98.9592
50-day SMA
Sell
Level $112.88
MACD (12, 26)
Sell
Level -3.83
25-day Aroon Oscillator
Sell
Level -92
On Balance Volume
Neutral
Level 404.4M

Financial Scores

Hold
Altman Z-Score (Annual)
Level (2.8366)
Sell
CA Score (Annual)
Level (-0.6899)
Sell
Beneish M-Score (Annual)
Level (-1.4539)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-2.1179)
Buy
Piotroski F Score (Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Stock Forecast FAQ

In the current month, SRPT has received 12 Buy ratings 1 Hold ratings, and 1 Sell ratings. The SRPT average analyst price target in the past 3 months is $178.55.

  • Where Will Sarepta Therapeutics Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Sarepta Therapeutics share price will rise to $178.55 per share over the next 12 months.

  • What Do Analysts Say About Sarepta Therapeutics?

    Analysts are divided on their view about Sarepta Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sarepta Therapeutics is a Sell and believe this share price will drop from its current level to $75.00.

  • What Is Sarepta Therapeutics's Price Target?

    The price target for Sarepta Therapeutics over the next 1-year time period is forecast to be $178.55 according to 14 Wall Street analysts, 12 of them rate the stock a Buy, 1 rates the stock a Sell, and 1 analyst rates the stock a Hold.

  • Is SRPT A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Sarepta Therapeutics is a Buy. 12 of 14 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of SRPT?

    You can purchase shares of Sarepta Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sarepta Therapeutics shares.

  • What Is The Sarepta Therapeutics Share Price Today?

    Sarepta Therapeutics was last trading at $97.17 per share. This represents the most recent stock quote for Sarepta Therapeutics. Yesterday, Sarepta Therapeutics closed at $97.19 per share.

  • How To Buy Sarepta Therapeutics Stock Online?

    In order to purchase Sarepta Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Goldman Sachs Stock a Buy Sell or Hold?
Is Goldman Sachs Stock a Buy Sell or Hold?

When the Federal Reserve started hiking rates in 2022, banks’…

Is Reddit a Buy on the Dip?
Is Reddit a Buy on the Dip?

Reddit (NYSE:RDDT) share price has been on the proverbial ropes…

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock